By Fineline Cube 
Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising over RMB 300 million (approximately USD 44.1 million). The round was led by Walvax Biotechnology Co., Ltd. (SHE: 300142), with participation from existing investor TaiLong VC, Qianhai Ark Venture Capital, and Shenzhen Credit Guarantee. Proceeds will accelerate the global clinical development of the company’s core pipeline assets across cardiovascular, metabolic, and infectious disease indications.
Financing Details
| Parameter | Detail |
|---|---|
| Round | Series C |
| Amount Raised | RMB 300+ million (USD 44.1 million) |
| Lead Investor | Walvax Biotechnology Co., Ltd. (SHE: 300142) |
| Participating Investors | TaiLong VC, Qianhai Ark Venture Capital, Shenzhen Credit Guarantee |
| Use of Proceeds | Global clinical development of core pipeline assets |
Founded in 2018, CureGene has rapidly advanced multiple first-in-class and next-generation therapeutic candidates through strategic drug design and innovative mechanisms of action.
Core Pipeline Assets
Evategrel – First-in-Class P2Y12 Inhibitor
- Formulations: Both intravenous and oral
- Innovation: Thiol-hydrolyzing prodrug design
- Onset of Action: <15 minutes (IV); <30 minutes (oral)
- Key Advantage: Completely overcomes “clopidogrel resistance” affecting ~58% of Chinese population
- Market Opportunity: Addresses significant unmet need in antiplatelet therapy for acute coronary syndromes
CG-0416 – Next-Generation THR-β Agonist
- Mechanism: Highly selective liver-targeting thyroid hormone receptor beta (THR-β) agonist
- Indications: Weight management and metabolic liver disease
- Development Stage: Phase I clinical trials initiated
- Therapeutic Rationale: Liver-specific targeting minimizes systemic side effects while maximizing metabolic benefits
CG-1999 – Hepatitis B Functional Cure Vaccine
- Mechanism: Therapeutic vaccine inducing specific immune responses against hepatitis B virus (HBV)
- Combination Potential: Demonstrates clear synergistic effects with siRNA/ASO therapies in animal models
- Key Outcomes:
- Accelerated reduction of hepatitis B surface antigen (HBsAg)
- Effective suppression of viral rebound after siRNA/ASO discontinuation
- Strategic Significance: Addresses functional cure paradigm in chronic HBV infection
Strategic & Market Context
- Cardiovascular Innovation: Evategrel’s ability to overcome clopidogrel resistance represents a major advancement for China’s large cardiovascular patient population
- Metabolic Disease Focus: CG-0416 enters the competitive but high-value NASH/obesity market with differentiated liver-targeting approach
- HBV Cure Strategy: CG-1999 positions CureGene in the emerging functional cure space for hepatitis B, a significant burden in Asia
- Global Ambitions: Funding specifically allocated for global clinical development signals international commercial aspirations
- Investor Validation: Walvax’s lead investment demonstrates confidence in CureGene’s platform and pipeline quality
This financing round provides CureGene with substantial resources to advance multiple high-potential assets simultaneously, positioning the company as an emerging player in China’s innovative biopharmaceutical landscape.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, financing outcomes, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions.-Fineline Info & Tech